Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Manoj Kesarwani

Interventional Cardiology Sacramento, CA Medical Doctor

NPI 1386836484 CMS profile 1291173

4860 Y St, Suite 2820, Sacramento, CA 95817

Open in the dashboard

General payments

$41,205

141 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$6,680 paid to institutions, not to them · program year 2019

Through program year 2025, Manoj Kesarwani of Sacramento, CA is reported in the CMS Open Payments database as having received $41,205 across 141 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $6,680 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 84th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,055 21
2024 General $704 11
2023 General $596 14
2022 General $32,626 44
2021 General $4,238 26
2020 General $224 7
2019 General $762 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Manoj Kesarwani
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Manoj Kesarwani were reported at $2,055. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Manoj Kesarwani Interventional Cardiology median Middle half National median
2019 $762 $1,097 $329–$3,048 $163
2020 $224 $473 $161–$1,480 $114
2021 $4,238 $677 $233–$1,827 $132
2022 $32,626 $978 $333–$2,724 $149
2023 $596 $1,136 $382–$2,986 $160
2024 $704 $1,181 $395–$3,326 $164
2025 $2,055 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $35,993 25 payments
  2. Philips Electronics North America Corporation $2,269 24 payments
  3. Boston Scientific Corporation $533 30 payments
  4. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $512 6 payments
  5. Biotronik Inc. $475 6 payments
  6. Cardiovascular Systems Inc. $229 7 payments
  7. Medtronic, Inc. $223 3 payments
  8. Shockwave Medical, Inc $213 15 payments
  9. HeartFlow, Inc. $203 1 payment
  10. AstraZeneca Pharmaceuticals LP $123 1 payment
  11. Other $432 23 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $33,625 8 payments
  2. Food and Beverage $4,268 114 payments
  3. Travel and Lodging $3,196 18 payments
  4. Education $117 1 payment
Products named General payments · program years 2019–2025
  1. SUPERA $22,625 1 payment
  2. DRAGONFLY OPSTAR $5,329 12 payments
  3. PRESSUREWIRE $4,000 1 payment
  4. Dragonfly OCT $3,755 5 payments
  5. Coronary Other $1,576 14 payments
  6. LifeVest $512 6 payments
  7. FFRct $203 1 payment
  8. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $194 14 payments
  9. (9266) ELCA $193 3 payments
  10. SYNERGY $172 8 payments
  11. Other $2,770 82 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

833

Median for Interventional Cardiology: 2,236

Drug cost

$351,607

Median for Interventional Cardiology: $380,412

Branded share of claims

40.8%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 74 $106,354
Repatha Sureclick Evolocumab Brand 54 $58,666
Praluent Pen Alirocumab Brand 61 $55,890
Brilinta Ticagrelor Brand 45 $53,217
Entresto Sacubitril/Valsartan Brand 22 $42,829
Jardiance Empagliflozin Brand 13 $20,785
Dabigatran Etexilate Dabigatran Etexilate Mesylate Brand 21 $5,671
Metoprolol Succinate Generic 69 $1,869
Rosuvastatin Calcium Generic 86 $1,833
Atorvastatin Calcium Generic 85 $1,299

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 62 billing codes

Paid by Medicare

$106,532

Medicare's payments for the services billed

Medicare patients

619

Average age 74

Services billed

1,732

291 women, 328 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 58%
Heart failure 53%
Arthritis 48%
Atrial fibrillation 43%
Diabetes 37%
Chronic kidney disease 36%
COPD 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
  • AstraZeneca Pharmaceuticals LP $123
$123 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

141 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record